Skip to content
Screener

Reported November 4, 2026 · After market close

Revenue$53.2MBeat by $181.8K
EPS-$0.05Beat by $0.02
Revenue estimate$53.0M
EPS estimate-$0.07
“We delivered another solid third quarter, with growth led by the U.S., where revenue grew 12%, and double-digit growth in our service business. Demand for our high-end instruments remained strong, with high-end Full Spectrum Profiling instrument revenue up 11% and Aurora Evo placements nearly doubling year over year. We also expanded gross margin by nearly 600 basis points. Looking ahead, we are reiterating the midpoint of our full-year revenue guidance and expect a strong finish to the year. We are well positioned to keep gaining market share, with our new product launches continuing to strengthen our technology leadership.”
Wenbin Jiang

Next report

Date not yet announced

Financials

Q3 2026

Income statement

See full
Revenue$53.2M+1.8%
Gross profit$31.2M+13.3%
Operating income-$8.4M+8.4%
Net income-$6.1M-11.3%
EPS (diluted)-$0.05-25.0%

Balance sheet

See full
Cash & equivalents$66.8M-28.4%
Total debt$16.3M-5.3%
Total equity$321.4M-15.1%
Total assets$446.1M-9.9%

Cash flow

See full
Operating cash flow-$4.5M-14.2%
CapEx$1.5M+129%
Free cash flow-$6.0M-30.8%

Valuation & ratios

Valuation

as of 11/10/26
See full
Market cap$770.32M+26.8%
Enterprise value$719.85M+35.5%
P/S3.7×+0.6×

Profitability

See full
Gross margin54.7%+1.3pp
Operating margin-21.1%—
Net margin-39.1%—
FCF margin-6.5%-45.1pp

Returns & leverage

See full
Return on equity-23.2%—
Debt / equity0.1×0.0×
Current ratio4.5×-0.7×

Segments

By geography

See full
EMEA$12.5M+1.0%
APAC$8.3M-25.5%
Other$2.1M+32.3%

By segment

See full
Reportable Segment$53.2M+1.8%

By product

See full
Service$16.1M+13.3%

FAQ

When did Cytek Biosciences, Inc. report Q3 2026 earnings?
Cytek Biosciences, Inc. (CTKB) reported Q3 2026 earnings on November 4, 2026 after market close.
What were Cytek Biosciences, Inc.'s Q3 2026 revenue and EPS?
Cytek Biosciences, Inc. reported revenue of $53.2M and eps of $-0.05 for Q3 2026.
Did Cytek Biosciences, Inc. beat estimates in Q3 2026?
Revenue beat the consensus estimate of $53.0M by $181.8K. EPS beat the consensus estimate of $-0.07 by $0.02.
How did Cytek Biosciences, Inc.'s Q3 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 1.8% from $52.3M a year earlier and eps declined 400.0% from $-0.01.
Where can I find Cytek Biosciences, Inc.'s Q3 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-447300) and the 10-Q periodic report (0001628280-26-070259) directly on SEC EDGAR. The filing index links above go to sec.gov.